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Influence of the renin-angiotensin system on epidermal growth Chronic cyclosporine (CsA)-induced nephrotoxicity is
factor expression in normal and cyclosporine-treated rat kidney. characterized by progressive renal failure and irrevers-
Background. Epidermal growth factor (EGF) plays an im- ible renal striped interstitial fibrosis, tubular atrophy,portant role in renal tubular regeneration after ischemic injury
and hyalinosis of the afferent arteriole [1]. The precisein kidney. The present study reports the association between
mechanism of chronic CsA nephrotoxicity is not wellthe renin-angiotensin system (RAS) and EGF, and the effect
of angiotensin II blockade with losartan (LSRT) on EGF ex- understood, but has been attributed to sustained afferent
pression in an experimental model of chronic cyclosporine arteriolar vasoconstriction and arteriopathy [2, 3].
(CsA) nephrotoxicity in rats.
The lack of an animal model of chronic CsA nephro-Methods. Two separate experiments were performed. In the
toxicity has hampered the study of the mechanisms offirst experiment, rats on the normal-salt diet (NSD; 0.3%) or
low-salt diet (LSD; 0.05%) were treated with or without LSRT renal damage. However, a reproducible animal model
for four weeks. In the second experiment, rats on the NSD or of chronic CsA nephrotoxicity was established from the
LSD were given vehicle (VH group, olive oil, 1 mg/kg per day) observation that sodium depletion exacerbates CsAor CsA (15 mg/kg per day) or CsA (15 mg/kg per day) plus LSRT
nephrotoxicity [4, 5]. In this model, CsA treatment in(100 mg/L per day). Renal function, histopathology, TUNEL
staining, plasma renin activity (PRA), and the expression of rats on a low-salt diet (LSD) induced a histologic feature
renin and EGF were studied. similar to that described in patients on long-term CsA
Results. Normal rats on the LSD showed significantly in- therapy [6]. Salt depletion activates the renin-angioten-creased EGF expression (cortex, 2.6-fold; medulla, 1.7-fold)
sin system (RAS), which has been implicated in theand significantly decreased EGF expression with the LSRT
changes in renal hemodynamics and function that followtreatment compared with the rats treated with the NSD (cortex,
74.8 vs. 10%; medulla, 22.5 vs. 5%). In contrast, the CsA- CsA administration [7]. Furthermore, angiotensin-con-
treated rats on the LSD had a significantly lower EGF expres- verting enzyme inhibitor or angiotensin II (Ang II) re-
sion (cortex, 98 vs. 53%; medulla, 94 vs. 14%); however, con-
ceptor antagonist is effective in preventing interstitialcomitant administration of LSRT increased the EGF expres-
fibrosis [8] by inhibiting the expression of intrarenalsion (cortex, 91- vs. 3.8-fold; medulla, 19- vs. 2.4-fold) compared
with the rats on the NSD. In the normal and CsA-treated transforming growth factor-1 (TGF-1) [9].
LSD rats, EGF expression was well correlated with PRA. In Epidermal growth factor (EGF) is a 53-amino acid
addition, EGF expression was well correlated with the intersti-
(6.2 kD) polypeptide that stimulates the proliferationtial fibrosis score (r  0.664, P  0.01) or number of TUNEL-
and differentiation of epithelial cells as well as beingpositive cells (r  0.822, P  0.01) in CsA-treated LSD rats.
Conclusions. These results suggest that angiotensin II block- mitogenic for various other cell types in culture [10, 11].
ade with LSRT decreases EGF expression in normal rats on In addition, EGF is thought to be important in the main-
the LSD, but it protects EGF expression in CsA-induced neph- tenance of renal tubule integrity and in the tubular regen-rotoxicity. This finding provides a new perspective on the reno-
erative response to injury [12, 13]. Animal studies showprotection of angiotensin II blockade in chronic CsA nephro-
toxicity. that EGF accelerates renal tubular regeneration in rat
models of acute renal failure [14], whereas treatment
with anti-EGF antibody inhibits tubular cell prolifera-Key words: losartan, nephrotoxicity, progressive renal disease, intersti-
tial fibrosis, tubular atrophy, tubular regeneration, ischemic injury. tion during compensatory renal growth [15].
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kidneys, and urinary expression is well correlated with Protocol 1. (1) NSD rats received a 0.4% sodium con-
tent diet for four weeks (N  6). (2) NSD-LSRT ratscompensatory renal growth, suggesting decreased urinary
EGF excretion by ischemic or CsA-induced toxicity [16]. received a 0.4% sodium content diet plus LSRT
(100 mg/L) in the drinking water for 28 days (N  6).Di Paolo et al reported that the renal expression and
the urinary concentration of the EGF signal are ex- (3) LSD rats received a 0.05% sodium content diet for
four weeks (N 6). (4) LSD-LSRT rats received a 0.05%tremely weak or even absent in patients with acute rejec-
tion, acute tubular necrosis, and CsA nephrotoxicity [17]. sodium content diet and LSRT (100 mg/L) in the drink-
ing water for 28 days (N  6).Stein-Oakley et al reported that chronic renal allograft
rejection shows decreased expression of EGF in a rat Protocol 2. This study was designed to evaluate the
role of RAS in regulating EGF expression in CsA-treatedmodel [18]. These findings suggest that tubular damage
by ischemia, nephrotoxic drugs, or rejection decreases rat kidney and to examine the effect of blocking the AT1
receptor on EGF expression. The NSD or an LSD wasEGF expression.
The association of EGF expression and RAS is well administered to the each group. (1) The vehicle (VH)
group of rats received a daily subcutaneous injection ofknown from studies in vitro and in the developing kidney
[19]. Angiotensin II potentiates the mitogenic action of olive oil, 1 mg/kg for four weeks (N  6). (2) CsA rats
received a daily subcutaneous injection of CsA (15 mg/kg)EGF on proximal tubular cells [20], and the inhibition
of angiotensin II type 1 (AT1) receptors decreases the for four weeks (N  6). (3) CsA  LSRT rats received a
daily subcutaneous injection of CsA (15 mg/kg) and LSRTrenal expression of EGF in neonatal rats [21]. Based on
these observations, we hypothesized that EGF expression (100 mg/L) was added to the drinking water for four
weeks (N  6).may be influenced by RAS in chronic CsA nephrotox-
icity. To test this hypothesis, two separate experiments This dosage and route of administration for LSRT
were selected because they have been previously shownwere performed. First, we evaluated the difference in
EGF expression of normal rats on a low-salt diet (LSD) to blockade Ang II receptors significantly [22].
or a normal-salt diet (NSD), and evaluated the influence
Basic protocolof Ang II blockade on EGF expression. Second, EGF
expression was evaluated in CsA-treated rats with an After one week of the animals on the NSD or LSD,
weight-matched rats were randomly assigned to the dif-LSD or an NSD, and the influence of Ang II blockade
on EGF expression was evaluated in normal and CsA- ferent treatment groups. Daily body weights were re-
corded. After each treatment period, the systolic bloodtreated rat kidneys. Our study clearly demonstrates the
influences of RAS on intrarenal EGF expression in rats pressure was measured with a plethysmography using a
tail manometer-tachometer system (BP-2000; Visitechwith or without CsA treatment.
Systems, Apex, NC, USA), and 24-hour urine samples
were collected in metabolic cages (Nalge Co., Rochester,
METHODS
NY, USA). The following day, animals were anesthe-
Animals tized with ketamine, and a blood sample and tissue speci-
mens were obtained.Male Sprague-Dawley rats (Charles River, Wilming-
ton, MA, USA), weighing 225 to 250 g, were housed in
Functional studiesindividual cases in a temperature- and light-controlled
environment. They received the LSD (0.05% sodium; Urinary and serum creatinine was measured by a Co-
bas autoanalyzer (Roche Diagnostics, Div. Hoffman-LaTeklad Premier, Madison, WI, USA) or NSD (0.4%
sodium; Teklad Premier). NSD rats were pair fed with Roche Inc., Nutley, NJ, USA). The creatinine clearance
(CCr) was calculated using a standard formula. The whole-LSD animals.
blood CsA concentrations were measured by monoclonal
Drugs radioimmunoassay (Incstar Co., Stillwater, MN, USA).
Plasma renin activity (PRA) was measured by radio-Cyclosporine provided by Sandoz Research (East Han-
over, NJ, USA) was diluted in olive oil to a final con- immunoassay (Angiotensin I-Biotecx radioimmunoassay;
Biotecx, Friendswood, TX, USA).centration of 15 mg/mL. Losartan (LSRT), provided by
Cardiovascular Diseases Research, DuPont-Merck Phar-
Histologymaceutical (Wilmington, DE, USA) was dissolved in
sterile water to a final concentration of 100 mg/L. These histologic findings were evaluated as previously
described [23]. Tubulointerstitial fibrosis (TIF) was esti-
Experimental groups mated semiquantitatively using a color image analyzer
(Mustek Paragon 800 SP, Macintosh PowerPC 7100, NIHTwo separate experiments were conducted. The first ex-
periment (protocol 1) was designed to evaluate the role of Image version 1.5) by counting the percentage of injured
areas per field of cortex and medulla. Scores of 0 to 3RAS in regulating EGF expression in normal rat kidney.
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Table 1. Changes in cyclosporine A (CsA) whole blood level,were given as follows: score 0  normal interstitium;
systolic blood pressure (SBP), serum creatinine (SCr), andscore 0.5  5%; score 1.0  5 to 15%; score 1.5  16 creatinine clearance (CCr) in the different experimental groups
to 25%; score 2.0  26 to 35%; score 2.5  36 to 45%;
CsA level SBP SCr CCrand score 3.0  45%. ng/mL mm Hg mg/dL mL/min/100 g
NSDTdt-mediated dUTP-biotin nick end-labeling
VH 13811 0.550.02 0.550.02
(TUNEL) method CsA 3826310 15721a 0.800.09a 0.390.03a
CsALSRT 4273170 13912b 0.850.11a 0.380.12aCells undergoing apoptosis were identified by the LSD
ApopTag in situ apoptosis detection kit (Oncor, Gaith- VH 1275 0.570.02 0.610.08
CsA 3100380 1287 1.020.06a 0.310.06aersburg, MD, USA). The sections were dewaxed and
CsALSRT 3260520 1104ab 1.050.17a 0.300.05atreated with proteinase K and then incubated with equili-
Data are presented as mean values  SEM of six rats. Abbreviations are:bration buffer in a humidified chamber for 10 minutes at NSD, normal salt diet; VH, vehicle; LSRT, losartan.
a P  0.05 vs. VHroom temperature, followed by incubation with working-
b P  0.05 vs. CsAstrength Tdt enzyme solution in a humidified chamber
at 37C for two hours. The reaction was terminated by
incubation in working-strength stop/wash buffer for 30 min-
utes at 37C. After being rinsed with phosphate-buffered
saline (PBS), the sections were incubated with anti-digoxi- 1:10,000; Bio-Rad] for 30 minutes. Antibody-reactive
genin peroxidase in a humidified chamber for 30 minutes protein was detected using enhanced chemiluminescence
at room temperature. Sections were then incubated with (Amersham Life Science, Little Chalfont, Buckingham-
diaminobenzidine and 0.01% H2O2 for five minutes at shire, UK). Densitometric analysis was performed using
room temperature. After being rinsed with PBS, the sec- Gelexpert software (Nucleotech Corp., San Carlos, CA,
tions were counterstained with hematoxylin and exam- USA). Optical densities (mean  SEM) were obtained
ined by light microscopy. To quantitate TUNEL-positive after three determinations for each band.
cells, 16 fields of outer medulla were randomly selected
in each section and observed under a microscope (magni- Immunohistochemistry of EGF and renin
fication 400). The number of apoptotic cells was ex- Sections were dewaxed. Before incubation with pri-
pressed per 1000 of the total tubular cells in each section. mary antibody, the sections were blocked with normal
rabbit serum diluted 1:10 in 0.3% bovine serum albuminImmunoblotting for EGF
(BSA) for 30 minutes and incubated for two hours at
Kidneys were homogenized in RIPA [10 mmol/L Tris 4C in mouse antiserum against EGF (Biomedical Tech-
Cl, pH 7.6, 150 mmol/L NaCl, 1% (wt/vol) sodium deoxy- nologies Inc., Stoughton, MA, USA) diluted 1:200 in BSA.
cholate, 1% (vol/vol) Triton X-100, 0.1% (wt/vol) so- The sections were rinsed in TBS and incubated for 30
dium dodecyl sulfate, 1% (vol/vol) aprotinin, 2 mmol/L minutes in peroxidase-conjugated rabbit anti-mouse IgG
Na3VO4, and freshly added leupeptin (1 	g/mL), pep- (Jackson ImmunoResearch Laboratories Inc., West Grove,
statin (1 	g/mL), and 1 mmol/L phenylmethylsulfonyl
PA, USA). Sections were incubated with a mixture of
fluoride (PMSF)]. Homogenates were centrifuged at
0.05% 3,3
-diaminobenzidine and 0.01% H2O2 for five16,000  g for 15 minutes at 4C, and protein concentra-
minutes at room temperature, washed with Tris-HCl buf-tions were determined using a protein microassay of
fer, counterstained with hematoxylin, and examined byBradford method (Bio-Rad, Hercules, CA, USA). Ho-
light microscopy. The method for renin immunohisto-mogenates were heated at 94C for five minutes. Proteins
chemistry was same as EGF immunohistochemistry. Thewere separated by sodium dodecyl sulfate-polyacryl-
number of renin-positive glomeruli was counted per 50amide gel electrophoresis (SDS-PAGE) in 15% poly-
glomeruli.acrylamide gels and were electroblotted onto Bio-Blot
nitrocellulose (Costar, Cambridge, MA, USA). Nonspe-
Statistical analysiscific binding was blocked by incubating the blots for
Data reported are mean  SEM, and all statisticalone hour in 5% (wt/vol) nonfat milk. Epidermal growth
analyses were calculated with SYSTAT for Macintoshfactor was detected by incubating for one hour with a
version 5.2 (SYSTAT Inc., Chicago, IL, USA). Compari-polyclonal anti-EGF antibody (Santa Cruz Biotechnol-
sons between groups were done by analysis of varianceogy, Inc., Santa Cruz, CA, USA) diluted 1:1000. Primary
(Kruskal-Wallis test followed by Tukey or Dunnet test)antibody incubation was followed by six washes of Tris-
or unpaired t test. Nonparametric (Spearman) correla-buffered saline with 0.005% Tween 20 (TBS-T). The blot
tion coefficient was calculated. The level of statisticalwas then incubated with secondary antibody [goat–anti-
rabbit IgG-horseradish peroxidase (HRP) conjugate at significance was P  0.05.
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Fig. 1. Effect of angiotensin II blockade with
losartan (LSRT) on cyclosporine A (CsA)-
induced chronic nephropathy. (A) Vehicle-
treated rat kidney. (B) The sodium-depleted
animal treated with CsA. There is a diffuse
interstitial fibrosis, mononuclear cell infiltrate,
and tubular atrophy. (C ) CsA and LSRT-
treated rat kidney. Note the decrease in inter-
stitial fibrosis and tubular atrophy. Trichrome
stain, magnification 100.
RESULTS
Blood pressure and functional assessment
Table 1 shows the blood pressure and renal function
in the experimental groups. At four weeks, systolic blood
pressure was increased in the CsA group with an NSD,
but there was no significant change in the CsA group
with an LSD. The addition of LSRT decreased systolic
blood pressure compared with the VH group on the
NSD and LSD. The CsA group with an NSD and an
LSD showed a significant decrease in CCr and a significant
increase in serum creatinine compared with the VH
group (P  0.05, respectively). However, there were no
significant differences in CCr between CsA and CsA 
LSRT groups with NSD or LSD.
Histologic assessment
Fig. 2. Comparison of tubulointerstitial fibrosis (TIF) between the nor-Low salt diet rats treated with CsA had characteristic
mal-salt diet (NSD;) and the low-salt diet (LSD; ) ingesting vehiclemorphologic findings that were usually evident at four
(VH) or cyclosporine A (CsA)-treated rats. In the LSD rats, there was
weeks and were similar to the chronic human CsA renal a significant increase in TIF score in CsA-treated rats and a dramatic
decrease of TIF with LSRT treatment in CsA-treated rats. In contrast,lesions (Fig. 1B). Focal TIF, tubular atrophy, and mono-
there was no significant difference of TIF in rats with the NSD. *P nuclear inflammatory cell infiltration were observed. The
0.05 vs. NSD; #P  0.05 vs. VH; ##P  0.05 vs. CsA.
concurrent administration of LSRT dramatically decreased
TIF (Fig. 1C). When the extent of changes in TIF was
graded with a 0 to 3 semiquantitative score, there were
no differences in the TIF scores among VH (0.17 0.14), with LSRT treatment. Figure 4 shows the comparison
CsA (0.21  0.19), and CsA  LSRT groups (0.19  of TUNEL-positive cells in the CsA-treated rats on the
0.18) on a NSD. However, in the LSD group, there was NSD and LSD. In the NSD group, there was no signifi-
a significant increase in TIF score in the CsA group cant increase in the number of TUNEL-positive cells
compared with the VH group (2.07  0.56 vs. 0.19 
with CsA treatment compared with the VH group (4.80.13, P 0.05). The concomitant administration of LSRT
2.5 vs. 2.2  1.6, P  0.05), and LSRT treatment diddecreased the TIF score in comparison with the CsA
not affect apoptotic cell death (3.9  1.7). In the LSDgroup (1.25  0.25; Fig. 2).
group, CsA treatment increased the number of TUNEL-
Apoptoic cell death in CsA-treated rats positive cells compared with the VH group (52.1  15.5
vs. 2.3  0.9, P  0.05), and concomitant administrationFigure 3 shows TUNEL-staining in chronic CsA neph-
of LSRT significantly decreased the number of TUNEL-rotoxic rats on the LSD. In the VH group, TUNEL-posi-
positive cells (15.6  3.0) as compared with the CsAtive cells were rarely observed. The number of TUNEL-
positive cells increased with CsA treatment, but decreased group (P  0.05).
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Fig. 3. Apoptotic cell death in CsA-treated
rats with LSD. Photomicrographs show apo-
ptosis as detected by the TUNEL assay in VH
(A), CsA (B), and CsA  LSRT (C) groups
with the LSD. Note the marked increase in
TUNEL-positive cells (arrowheads) in the
CsA-treated rats and decrease in TUNEL-
positive cells in CsA  LSRT groups (magni-
fication 200).
Fig. 4. Comparison of TUNEL-positive cells of vehicle and CsA-
treated rats between those on the NSD () and the LSD ( ). There
was no significant change of TUNEL-positive cells in CsA-treated rat
kidney with NSD, but there was a significant increase of TUNEL-
positive cells in CsA-treated rats with the LSD. Concomitant adminis-
tration of CsA and LSRT decreased TUNEL-positive cells in rats with
LSD. *P  0.05 vs. NSD; #P  0.05 vs. VH; ##P  0.05 vs. CsA.
Activity of renin-angiotensin system in Fig. 5. Intrarenal renin expression in vehicle and CsA-treated rats. (A)
CsA-treated rats Immunohistochemistry of renin in VH and CsA groups. In the VH group,
there was minimal immunoreactivity of renin, but its immunoreactivityFigure 5 shows the intrarenal expression of renin and was strongly increased in the CsA-treated rat kidney (magnification
the results of quantitative analysis of renin-positive glo- 200). (B) Quantitative analysis of renin-producing glomeruli in the
VH or CsA-treated NSD and LSD rats. Note the significant increasemeruli in kidneys of CsA-treated rats on the NSD and
of renin-producing glomeruli in rats on the LSD compared with theLSD. Intrarenal expression of renin was minimal in the NSD, and the increase of renin-producing glomeruli in CsA-treated
VH group, but its immunoreactivity and number of re- LSD rats compared with NSD rats. *P  0.05 vs. NSD; **P  0.05 vs.
CsA  NSD; #P  0.05 vs. LSD.nin-positive glomeruli were increased in the kidneys with
CsA treatment. Quantitative analysis showed a signifi-
cant increase in the number of renin-positive glomeruli
in rats on the LSD compared with the NSD in the VH 5.6 vs. 3.1  1.7, P  0.05). CsA treatment increased
group (11  3 vs. 6  2, P  0.05). CsA treatment PRA in both the NSD (9.3  2.8) and the LSD (38.8 
increased renin-positive glomeruli compared with the 6.2) compared with the VH group (P  0.05, respec-
VH group in both the NSD and LSD, but a greater in- tively). The concomitant administration of LSRT sig-
crease was observed in the LSD group (25  2 vs. 15  nificantly increased PRA (26.3  5.0) in the NSD, but
3, P  0.05). there was a dramatic decrease of RPA in the LSD (7.0
In the VH group, PRA was significantly increased in 1.8) as compared with the CsA (P  0.05, respectively;
Fig. 6).the LSD group compared with the NSD group (13.8 
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Fig. 6. Comparison of plasma renin activity (PRA) between the NSD
() and the LSD ( ) CsA-treated rats. Quantitative analysis of renin- Fig. 7. Immunoblot of epidermal growth factor (EGF) expression in
positive glomeruli demonstrates a significant increase in the LSD as NSD and LSD rats. Note the significant increase of EGF expression in
compared with the NSD. CsA treatment also increased intrarenal ex- rats on a LSD compared with no significant change in EGF expression
pression of renin, and this increase was more definite in the LSD com- in those on a NSD. Concomitant administration of LSRT decreased
pared with NSD. *P  0.05 vs. NSD; #P  0.05 vs. VH; ##P  0.05 EGF expression in LSD rats, but no significant change was observed
vs. CsA. in NSD rats. *P  0.05 vs. NSD; #P  0.05 vs. LSD.
bules and in the thick ascending limb of Henle (Fig. 9A, B).
Influence of the renin-angiotensin system on EGF In the CsA group, immunoreactivity of EGF protein was
expression in normal rats almost undetectable in both renal tubular cells (Fig. 9C
The immunoblot and optical densities of EGF are and D), but concomitant administration of CsA and
shown in Figure 7. After four weeks on the LSD, EGF LSRT dramatically increased immunoreactivity of EGF
expression was significantly increased (cortex, 40  3 vs. in both tubules (Fig. 9E, F).
103  8; medulla, 77  15 vs. 151  19, P  0.05,
Relationship between plasma renin activity andrespectively) compared with the rat kidney with the NSD
EGF expression(Fig. 7). A concomitant administration of LSRT did not
affect EGF expression in the NSD, but there was a sig- The association between RAS with EGF expression
nificant decrease of EGF expression in rats with the LSD was evaluated in normal and CsA-treated rats (Fig. 10).
(cortex, 103  8 vs. 26  5; medulla, 151  19 vs. 117  With the LSD, EGF expression was positively correlated
16, P  0.05, respectively). with PRA in normal rats (cortex, r  0.847; medulla,
r  0.899), but was negatively correlated with PRA in
Influence of the renin-angiotensin system on EGF CsA-treated rats (cortex, r  0.747; medulla, r  0.722).
expression in CsA-treated rats
Association between EGF expression andThe immunoblot and optical density of EGF are
interstitial fibrosis or apoptotic cell deathshown in Figure 8. Immunoblotting for EGF protein
in chronic CsA nephrotoxicityprovided a single band at 6 kD. In the NSD group, CsA
treatment for four weeks significantly decreased EGF The association between EGF expression and apoptotic
expression (cortex, 81  8 vs. 38  3; medulla, 85  9 cell death or interstitial fibrosis in chronic CsA nephro-
vs. 73  6, P  0.05, respectively), and CsA treatment toxicity was evaluated (Fig. 11). Epidermal growth factor
in the LSD group almost completely inhibited EGF ex- expression was well correlated with TIF (r  0.664, P 
pression (cortex, 94  10 vs. 2.0  0.5; medulla, 219  0.01) and the number of TUNEL-positive cells (r 
24 vs. 14 2.5, P 0.05, respectively). With a concurrent 0.822, P  0.01).
administration of LSRT, EGF expression was signifi-
cantly increased in the NSD (vs. 182  17, P  0.05)
DISCUSSIONand the LSD (vs. 269  19, P  0.05).
The results of our study clearly demonstrate EGF ex-
Immunohistochemistry of EGF pression in normal and CsA-treated rat kidneys according
to the status of RAS. In normal rats, EGF expressionImmunostaining of EGF in the VH group showed well-
localized immunoreactivity in the distal convoluted tu- was significantly higher in rats on the LSD compared
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Fig. 8. Immunoblot of EGF in (A) NSD and
(B) LSD CsA-treated rats. Note that CsA-
treated rats on the LSD almost inhibited EGF
expression compared with the rats on the NSD.
Administration of LSRT increased EGF ex-
pression in rats on the NSD and the LSD, but
a greater increase was observed in LSD rats.
*P  0.05 vs. VH; **P  0.01 vs. VH; #P 
0.05 vs. CsA; ##P  0.01 vs. CsA.
with the NSD rats, and inhibition of EGF expression pared with the NSD rats. This finding confirms that acti-
vation of RAS with an LSD is essential to induce theby LSRT was observed only in rats on the LSD. On the
other hand, CsA-treated rats showed a decreased EGF pathologic lesion of chronic CsA nephrotoxicity and that
LSD augments activation of RAS by CsA.expression, but Ang II blockade with LSRT preserved
the EGF expression, with the effect being more definite Our study clearly demonstrates that EGF expression
in the kidney is regulated by the activity of RAS in normalin the LSD rats. This finding suggests that EGF expres-
sion is influenced by the status of RAS in rat kidney. rats. To define the role of RAS in regulating EGF expres-
sion, diets of different sodium contents (NSD vs. LSD)The RAS plays an important role in the pathogenesis
of the experimental model of chronic CsA nephrotoxic- were used. The rats on an LSD showed a significantly
increased EGF expression compared with the rats on anity [7]. CsA administration in salt-depleted rats causes
a significant increase in juxtaglomerular apparatus renin, NSD (cortex, 2.6-fold; medulla, 1.7-fold). In addition,
LSRT treatment significantly decreased the EGF expres-and CsA-induced interstitial fibrosis could be prevented
by the use of LSRT or enalapril [8]. Others have demon- sion in LSD rats, but there was no significant decrease
in EGF expression in NSD rats (cortex, 74.8 vs. 10%;strated a beneficial effect with Ang II blockade on CsA-
induced afferent arteriolopathy and a decrease in the mac- medulla, 22.5 vs. 5%). Moreover, EGF expression was
well correlated with PRA (cortex, r  0.847; medulla, r rophage chemoattractant osteopontin [23]. In the present
study, typical chronic CsA nephrotoxicity was observed 0.899). Based on these observations, we propose that
EGF expression in the normal rat kidney is dependentonly in the LSD rats. In addition, CsA with LSD further
increased PRA and intrarenal expression of renin com- on the activity of RAS.
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Fig. 9. Immunohistochemistry of EGF in VH
(A and B), CsA (C and D), and CsA LSRT
(E and F)-treated groups on the LSD. In the
VH group, moderate immunoreactivity of
EGF was observed in the distal convoluted
tubules (A) and the thick ascending limb of
Henle (B). With CsA treatment, the immuno-
reactivity of two tubules was almost absent (C
and D). Concomitant administration of LSRT
markedly increased the immunoreactivity of
EGF in the distal convoluted tubules (E) and
the thick ascending limb of Henle (F). Magni-
fication 200.
In contrast to rats not receiving CsA treatment, EGF is conceivable that CsA has a direct toxic effect on EGF
expression; the LSD, which enhances the hemodynamicexpression decreased in CsA-treated rats on both diets,
but a more significant decrease was observed in rats with effect of Ang II, might potentiate this effect.
One interesting finding in this study is the overexpres-the LSD compared with the NSD (cortex, 98 vs. 53%;
medulla, 94 vs. 14%). The same result was also observed sion of EGF with the Ang II blockade in CsA-treated
NSD rats (cortex, 1.9-fold; medulla, 2.0-fold) or with thewhen LSRT and CsA were coadministered. The Ang II
blockade significantly increased EGF expression in LSD LSD (cortex, 2.0-fold; medulla, 1.2-fold) compared with
the VH group. This finding suggests that the mechanismand NSD rats, but a more significant decrease was ob-
served in rats on the LSD compared with the NSD (cor- of preservation of EGF expression by LSRT is more than
that of a reduced CsA-induced nephrotoxicity, and thattex, 91- vs. 3.8-fold; medulla, 19- vs. 2.4-fold). In addition,
EGF expression was negatively correlated with PRA in RAS may be involved in the process of EGF synthesis
in CsA-treated rats. In general, EGF is synthesized as arats on the LSD (cortex, r  0.749; medulla, r  0.722).
This finding suggests that enhanced CsA-induced neph- transmembrane prepro-EGF molecule [24, 25], which is
a membrane-attached protein with a membrane-span-rotoxicity by LSD overcomes the action of Ang II, which
increases EGF expression in normal rats. In addition, it ning hydrophobic domain adjacent to the EGF moiety
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Fig. 10. Association of EGF expression with
PRA in (A) normal and (B) CsA-treated rats
on the LSD. N  12 and P  0.01 in every
group. In A, r  0.847 in cortex and 0.899 in
medulla; in B, r  0.749 in cortex and 0.722
in medulla. EGF expression showed a positive
correlation with PRA in normal rats, but
showed negative correlation with PRA in
CsA-treated rats.
[26]. The EGF precursor is not processed to the small Henle and distal convoluted tubules. With CsA treat-
ment, the intensity of EGF immunoreactivity was almostpeptide in the kidney [27] nor is it easily solubilized from
the cell membrane during the extraction process [28]. undetectable in both tubules. In the CsALSRT group,
the immunoreactivity of EGF was markedly increasedBased on the previously mentioned findings, we can spec-
ulate on some possible mechanisms to explain the over- in both tubules, which showed more increased immuno-
reactivity of EGF when compared with the VH group.expression of EGF by LSRT in the CsA-treated rat kid-
ney. First, the Ang II blockade may increase the cleavage This immunohistochemical finding is consistent with the
immunoblot result and clearly shows the inhibitory effectof a preformed precursor in CsA-treated rats. Second,
the Ang II blockade may inhibit the secretion of a mature of CsA and the protective effect of LSRT treatment on
EGF expression in chronic CsA nephrotoxicity.form of EGF in CsA-treated rats. Third, there might be
a feedback mechanism between RAS and EGF expres- The molecular mechanism of EGF as a growth factor
was studied extensively in an experimental model ofsion in the CsA-treated rat kidney. An in vitro study is
needed to define the relationship between EGF expres- ischemia/reperfusion injury, and data exist in favor of
an involvement of EGF in regenerative hyperplasia aftersion and RAS.
Previous studies have demonstrated that EGF is ex- renal injury. Exogenously added EGF has been demon-
strated to enhance renal tubule cell regeneration as wellpressed in the thick ascending limb of Henle and distal
convoluted tubules [29–31], which are vulnerable to CsA. as to lessen the severity and duration of acute renal
failure after hypoxic injury [32, 33] or exposure to variousIn our current study, the VH group showed moderate
immunostaining for EGF in the thick ascending limb of nephrotoxins such as mercuric chloride [34], folic acid
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fibrosis in CsA-induced nephropathy. Moreover, the
protective effect on EGF expression by LSRT might be
associated with improvements in both parameters. As
expected, EGF expression was well correlated with inter-
stitial fibrosis (r 0.664) and TUNEL-positive cells (r
0.822). This finding suggests that the loss of endogenous
EGF during chronic CsA nephrotoxicity is associated
with increased apoptotic cell death resulting in interstitial
fibrosis. On the other hand, experimental approaches
aiming to block EGF receptor signaling seem to amelio-
rate the evolution of renal diseases. Terzi et al reported
a reduction of TIF after renal injury in mice with targeted
tubular expression of a dominant negative EGF receptor
[39]. This finding suggests that inhibition of EGF signal-
ing in the kidney may prevent the development of renal
lesions after renal injury. At present, the fate of EGF
receptor in renal tissues exposed to CsA or LSRT is un-
known because our experimental investigations focused
on EGF itself. However, we suggest that intrarenal EGF
may be associated with healing processes, but that it may
be helpful or harmful according to the clinical situation.
When the kidney is damaged by ischemic or toxic injury,
EGF may act as a growth factor in the regeneration of
renal tubular cells. In contrast, EGF may have a harmful
action in the progression of renal disease in an animal
model of uremia (5/6 nephrectomy model).
Our study clearly demonstrates that EGF expression
is influenced by the status of RAS in normal and CsA-
treated rats. EGF expression is decreased by CsA, but is
protected by the Ang II blockade with LSRT. This finding
provides a new perspective to the renoprotection of Ang II
blockade in cases of chronic CsA nephrotoxicity.
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